Trial Profile
A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Osteosarcoma; Pancreatic cancer; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 02 Aug 2023 added osteosarcoma for bone sarcoma, line of therapy is not clear for sarcoma.
- 25 Jul 2023 Status changed from active, no longer recruiting to completed.
- 21 Aug 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2023.